Elanco Animal Health Incorporated $ELAN Shares Sold by Douglas Lane & Associates LLC

Key Points

• Hedge fund Douglas Lane & Associates cut its stake in Elanco by 11.5%, selling 396,176 shares and leaving it with 3,048,092 shares (about 0.61% of the company) valued at roughly $68.98 million.
• Elanco topped Q4 expectations with $0.13 EPS and revenue of $1.14 billion (up 12.2% year-over-year), and issued Q1 2026 guidance of $0.33–0.36 EPS and FY 2026 guidance of $1.00–1.06 EPS.
• Wall Street sentiment is mostly positive (average rating: Moderate Buy) with a consensus price target of $27.67; the stock has a market cap of about $11.67 billion and a 52-week range of $8.02–$27.72.

Douglas Lane & Associates LLC cut its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 11.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,048,092 shares of the company's stock after selling 396,176 shares during the quarter. Douglas Lane & Associates LLC owned approximately 0.61% of Elanco Animal Health worth $68,978,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. SJS Investment Consulting Inc. lifted its holdings in Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company's stock valued at $28,000 after acquiring an additional 1,333 shares during the period. Huntington National Bank lifted its holdings in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company's stock valued at $38,000 after acquiring an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock valued at $42,000 after acquiring an additional 900 shares during the period. Farther Finance Advisors LLC increased its position in shares of Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock valued at $43,000 after buying an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company's stock valued at $58,000 after buying an additional 2,807 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Down 0.6%

Shares of ELAN opened at $23.47 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $27.72. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of -48.89, a PEG ratio of 3.00 and a beta of 1.88. The stock has a 50 day moving average price of $24.46 and a 200 day moving average price of $22.91.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.09 billion. During the same period in the previous year, the business earned $0.14 earnings per share. The firm's revenue for the quarter was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ELAN. UBS Group restated a "buy" rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Weiss Ratings restated a "sell (d+)" rating on shares of Elanco Animal Health in a research report on Friday, March 27th. Morgan Stanley boosted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 25th. KeyCorp boosted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Finally, Leerink Partners boosted their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an "outperform" rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $27.67.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.